Galectin Therapeutics Inc.
$2.29
▼
-0.37%
2026-04-21 07:00:01
galectintherapeutics.com
NCM: GALT
Explore Galectin Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$156.67 M
Current Price
$2.29
52W High / Low
$7.13 / $1.21
Stock P/E
—
Book Value
$-1.97
Dividend Yield
—
ROCE
-174.62%
ROE
26.9%
Face Value
—
EPS
$-0.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
1.04
Debt / Equity
-1.06
Current Ratio
2.42
Quick Ratio
2.42
Forward P/E
-1.37
Price / Sales
—
Enterprise Value
$273.62 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$11
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Harmony Biosciences Holdings, Inc. | $29.53 | 10.93 | $1.73 B | — | 20.45% | 20.75% | $40.87 / $25.52 | $15.07 |
| 2. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 3. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 4. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 5. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 6. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 7. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.37 M | -4.2 M | -4.62 M | -7.9 M | -12.43 M | — |
| Net Profit | -5.5 M | -8.18 M | -7.52 M | -9.63 M | -11.97 M | — |
| EPS in Rs | -0.08 | -0.12 | -0.11 | -0.15 | -0.18 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -20.09 M | -42.43 M | -38.07 M | -38.35 M |
| Net Profit | -30.84 M | -47.05 M | -41.07 M | -38.78 M |
| EPS in Rs | -0.47 | -0.71 | -0.62 | -0.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.53 M | 17.5 M | 28.2 M | 21.29 M |
| Total Liabilities | 145.73 M | 120.56 M | 88.44 M | 53.48 M |
| Equity | -126.19 M | -103.07 M | -60.24 M | -32.19 M |
| Current Assets | 19.44 M | 17.25 M | 27.71 M | 20.55 M |
| Current Liabilities | 8.03 M | 35.41 M | 15.68 M | 13.01 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.88 M | -41.77 M | -32.97 M | -31.06 M |
| Investing CF | 0 M | 0 M | 0 M | 0 M |
| Financing CF | 26.48 M | 31.23 M | 40.03 M | 10 M |
| Free CF | -23.88 M | -41.77 M | -32.97 M | -31.06 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 34.46% | -14.56% | -5.91% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.